Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H936
UPID:
GHC1_HUMAN
Alternative names:
Glutamate/H(+) symporter 1; Solute carrier family 25 member 22
Alternative UPACC:
Q9H936; A8K366; C9J1H6; E9PJD3; E9PKB2; E9PL68; E9PN26; E9PNQ3; E9PP01; E9PR97; Q8TBU8
Background:
Mitochondrial glutamate carrier 1, also known as Glutamate/H(+) symporter 1 and Solute carrier family 25 member 22, plays a crucial role in transporting glutamate from the cytosol into the mitochondrial matrix. This process is vital for maintaining cellular energy balance and is linked to glucose-stimulated insulin secretion.
Therapeutic significance:
The protein is implicated in Developmental and epileptic encephalopathy 3 (DEE3), a severe form of epilepsy with no effective treatment. Understanding the role of Mitochondrial glutamate carrier 1 in DEE3 could pave the way for novel therapeutic strategies, potentially transforming patient outcomes.